Allakos Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLK research report →
Companywww.allakos.com
Allakos Inc. , a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
- CEO
- Robert Alexander
- IPO
- 2018
- Employees
- 131
- HQ
- San Carlos, CA, US
Price Chart
Valuation
- Market Cap
- $29.74M
- P/E
- -1.15
- P/S
- 7.65
- P/B
- 0.53
- EV/EBITDA
- -0.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.00%
- Op Margin
- -706.50%
- Net Margin
- -663.39%
- ROE
- -38.44%
- ROIC
- -49.55%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-115,818,000 · 37.63%
- EPS
- $-1.30 · 39.25%
- Op Income
- $-122,225,000
- FCF YoY
- 19.93%
Performance & Tape
- 52W High
- $1.56
- 52W Low
- $0.22
- 50D MA
- $0.27
- 200D MA
- $0.74
- Beta
- 0.14
- Avg Volume
- 2.85M
Get TickerSpark's AI analysis on ALLK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 25 | BVF PARTNERS L P/IL | sell | 855,211 |
| May 15, 25 | Walker Paul Edward | sell | 3,386,400 |
| May 15, 25 | Walker Paul Edward | sell | 37,600 |
| May 15, 25 | Walker Paul Edward | sell | 16,000 |
| May 15, 25 | Walker Paul Edward | sell | 7,700 |
| May 15, 25 | Walker Paul Edward | sell | 7,700 |
| May 15, 25 | Walker Paul Edward | sell | 99,590 |
| May 15, 25 | Walker Paul Edward | sell | 86,762 |
| May 15, 25 | Walker Paul Edward | sell | 41,000 |
| May 15, 25 | Tomasi Adam | sell | 1,200,000 |
Our ALLK Coverage
We haven't published any research on ALLK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALLK Report →